Topic: manufacturing safety
Tests in diabetes drug metformin for suspected carcinogens by a independent laboratory contradict those conducted by the FDA.
Only months after widespread recalls of Zantac, Mylan is now taking back lots of nizatidine after finding trace amounts of probable carcinogen.
Bayer is recalling two lots of its top-selling drugs after a labeling mishap led to them being filled with the wrong hemophilia medicines.
An explosion at a pharmaceutical manufacturing facility has again claimed the lives of workers.
Athenex has voluntarily suspended production at its Chongqing, China, API facility in the wake of explosions earlier this year.
Swiss pharma and chemical supplier Lonza will carve out its Specialty Ingredients business as part of its effort to reorganize the slumping division.
India’s Cadila found a ray of sunshine in the fact that the FDA issued 14 observations during an inspection of its formulation plant in Moraiya.
As the FDA works to contain the damage from a massive recall of blood pressure drugs, litigation stemming from the mess is just getting started.
Indian drugmakers pick up U.S. generics scripts; Chi-Med files for Hong Kong listing; an explosion at a Qilu Pharma subsidiary kills 10.
As a key global ingredient supplier, problems in China can ripple worldwide as they have for Swiss CDMO Lonza.